PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
15831814-8	2005	In those cells, the AT4 antagonist divalinal diminished dose-dependently Ang IV-induced NF-kappaB activation and prevented IkappaB degradation, but had no effect on the Ang II response, indicating that Ang IV activates the NF-kappaB pathway via AT4 receptors.	divalinal	35-44	immunoglobulin kappa variable 4-55	Mus musculus	20-23
18806625-5	2008	The AT2 receptor antagonist PD123319 and the AT4 receptor antagonist divalinal abolished the protective effect of 5 days" AT1 blockade.	divalinal	69-78	angiotensin II receptor, type 1a	Rattus norvegicus	122-125
15831814-8	2005	In those cells, the AT4 antagonist divalinal diminished dose-dependently Ang IV-induced NF-kappaB activation and prevented IkappaB degradation, but had no effect on the Ang II response, indicating that Ang IV activates the NF-kappaB pathway via AT4 receptors.	divalinal	35-44	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	73-76
15831814-8	2005	In those cells, the AT4 antagonist divalinal diminished dose-dependently Ang IV-induced NF-kappaB activation and prevented IkappaB degradation, but had no effect on the Ang II response, indicating that Ang IV activates the NF-kappaB pathway via AT4 receptors.	divalinal	35-44	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	88-97
15831814-8	2005	In those cells, the AT4 antagonist divalinal diminished dose-dependently Ang IV-induced NF-kappaB activation and prevented IkappaB degradation, but had no effect on the Ang II response, indicating that Ang IV activates the NF-kappaB pathway via AT4 receptors.	divalinal	35-44	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	223-232
15831814-8	2005	In those cells, the AT4 antagonist divalinal diminished dose-dependently Ang IV-induced NF-kappaB activation and prevented IkappaB degradation, but had no effect on the Ang II response, indicating that Ang IV activates the NF-kappaB pathway via AT4 receptors.	divalinal	35-44	immunoglobulin kappa variable 4-55	Mus musculus	245-248
10572242-6	1999	As expected, internalization of (125)I-Ang IV was completely abolished by divalinal-Ang IV, a known AT(4) receptor antagonist.	divalinal	74-83	ANG	Bos taurus	39-42
10572242-6	1999	As expected, internalization of (125)I-Ang IV was completely abolished by divalinal-Ang IV, a known AT(4) receptor antagonist.	divalinal	74-83	ANG	Bos taurus	84-87
8958583-6	1996	Physiological studies in which test compounds were injected into the internal carotid of the rat and cerebral blood flor (CBF) was measured by laser Doppler flowmetry indicated that pretreatment with Divalinal-Ang IV, but not DuP 753 or PD123177, blocked the increased flow observed with Ang IV infusion.	divalinal	200-209	ANG	Bos taurus	210-213
8958583-6	1996	Physiological studies in which test compounds were injected into the internal carotid of the rat and cerebral blood flor (CBF) was measured by laser Doppler flowmetry indicated that pretreatment with Divalinal-Ang IV, but not DuP 753 or PD123177, blocked the increased flow observed with Ang IV infusion.	divalinal	200-209	angiogenin	Rattus norvegicus	288-291
30223703-2	2018	MATERIALS AND METHODS: Rats with CCH received central infusion of Ang IV, its receptor AT4R antagonist divalinal-Ang IV or artificial cerebrospinal fluid for six weeks.	divalinal	103-112	angiogenin	Rattus norvegicus	113-116
12021572-12	2002	This effect of angiotensin IV was blocked by the AT4 receptor blocker divalinal (10-6 M).	divalinal	70-79	leucyl and cystinyl aminopeptidase	Homo sapiens	49-61
11514021-10	2001	The enhancement of LTP can be prevented by pretreatment with Divalinal, an Ang IV antagonist, without any effect on normal LTP.	divalinal	61-70	angiogenin	Rattus norvegicus	75-78
11514021-15	2001	However, the inhibition by Ang IV was dose dependent and was blocked by Divalinal.	divalinal	72-81	angiogenin	Rattus norvegicus	27-30
26238445-7	2015	The beneficial effect of medium-dose Ang IV may be contributed to the stimulation of type 4 angiotensin receptor (AT4R) and AT2R with suppression of AT1R, activation of Akt, and inhibition of nuclear factor-kappaB, as these beneficial effects were largely reversed by cotreatment with the AT4R antagonist divalinal-Ang IV in Ang II-infused mice or with the Akt inhibitor A6730 in Ang II-stimulated human smooth muscle cells.	divalinal	305-314	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	37-40